The facial nerve palsy and cortisone evaluation (FACE) study in children: protocol for a randomized, placebo-controlled, multicenter trial, in a Borrelia burgdorferi endemic area

Sofia Karlsson, Sigurdur Arnason, Nermin Hadziosmanovic, Åsa Laestadius, Malou Hultcrantz, Elin Marsk, Barbro H Skogman, Sofia Karlsson, Sigurdur Arnason, Nermin Hadziosmanovic, Åsa Laestadius, Malou Hultcrantz, Elin Marsk, Barbro H Skogman

Abstract

Background: Children with acute peripheral facial nerve palsy cannot yet be recommended corticosteroid treatment based on evidence. Adults with idiopathic facial nerve palsy are treated with corticosteroids, according to guidelines resulting from a meta-analysis comprising two major randomized placebo-controlled trials. Corresponding trials in children are lacking. Furthermore, acute facial nerve palsy in childhood is frequently associated with Lyme neuroborreliosis, caused by the spirochete Borrelia burgdorferi. The efficacy and safety of corticosteroid treatment of acute facial nerve palsy associated with Lyme neuroborreliosis, has not yet been determined in prospective trials in children, nor in adults.

Method: This randomized double-blind, placebo-controlled study will include a total of 500 Swedish children aged 1-17 years, presenting with acute facial nerve palsy of either idiopathic etiology or associated with Lyme neuroborreliosis. Inclusion is ongoing at 12 pediatric departments, all situated in Borrelia burgdorferi endemic areas. Participants are randomized into active treatment with prednisolone 1 mg/kg/day (maximum 50 mg/day) or placebo for oral intake once daily during 10 days without taper. Cases associated with Lyme neuroborreliosis are treated with antibiotics in addition to the study treatment. The House-Brackmann grading scale and the Sunnybrook facial grading system are used for physician-assessed evaluation of facial impairment at baseline, and at the 1- and 12-month follow-ups. Primary outcome is complete recovery, measured by House-Brackmann grading scale, at the 12-month follow-up. Child/parent-assessed questionnaires are used for evaluation of disease-specific quality of life and facial disability and its correlation to physician-assessed facial impairment will be evaluated. Furthermore, the study will evaluate factors of importance for predicting recovery, as well as the safety profile for short-term prednisolone treatment in children with acute facial nerve palsy.

Discussion: This article presents the rationale, design and content of a protocol for a study that will determine the efficacy of corticosteroid treatment in children with acute facial nerve palsy of idiopathic etiology, or associated with Lyme neuroborreliosis. Future results will attribute to evidence-based treatment guidelines applicable also in Borrelia burgdorferi endemic areas.

Trial registration: The study protocol was approved by the Swedish Medical Product Agency (EudraCT nr 2017-004187-35) and published at ClinicalTrials.gov ( NCT03781700 , initial release 12/14/2018).

Conflict of interest statement

The authors declare that they have no competing interests. Furthermore, sponsor and funders have not been involved in the design of the study, and will not have any role during its execution, analyses, interpretation of the data or decision to submit results to scientific journals.

References

    1. Pitaro J, Waissbluth S, Daniel SJ. Do children with Bell's palsy benefit from steroid treatment? A systematic review. Int J Pediatr Otorhinolaryngol. 2012;76(7):921–926. doi: 10.1016/j.ijporl.2012.02.044.
    1. Lorch M, Teach SJ: Facial nerve palsy: etiology and approach to diagnosis and treatment. Pediatr Emerg Care 2010;26(10):763–69; quiz 770-763.
    1. Peitersen E. Bell's palsy: the spontaneous course of 2,500 peripheral facial nerve palsies of different etiologies. Acta Otolaryngol Suppl. 2002;549:4–30. doi: 10.1080/000164802760370736.
    1. Tveitnes D, Oymar K, Natas O. Acute facial nerve palsy in children: how often is it Lyme borreliosis? Scand J Infect Dis. 2007;39(5):425–431. doi: 10.1080/00365540601105764.
    1. Arnason S, Hultcrantz M, Nilsson A, Laestadius A. Peripheral facial nerve palsy in children in a Borrelia high-endemic area, a retrospective follow-up study. Acta Paediatr. 2020;109(6):1229-35.
    1. Stanek G, Strle F. Lyme borreliosis-from tick bite to diagnosis and treatment. FEMS Microbiol Rev. 2018;42(3):233–258. doi: 10.1093/femsre/fux047.
    1. Skogman BH, Croner S, Nordwall M, Eknefelt M, Ernerudh J, Forsberg P. Lyme neuroborreliosis in children: a prospective study of clinical features, prognosis, and outcome. Pediatr Infect Dis J. 2008;27(12):1089–1094. doi: 10.1097/INF.0b013e31817fd423.
    1. Mygland A, Ljostad U, Fingerle V, Rupprecht T, Schmutzhard E, Steiner I. EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol. 2010;17(1):8–16. doi: 10.1111/j.1468-1331.2009.02862.x.
    1. Rowhani-Rahbar A, Baxter R, Rasgon B, Ray P, Black S, Klein JO, Klein NP. Epidemiologic and clinical features of Bell's palsy among children in northern California. Neuroepidemiology. 2012;38(4):252–258. doi: 10.1159/000338303.
    1. Biebl A, Lechner E, Hroncek K, Preisinger A, Eisenkolbl A, Schmitt K, Furthner D. Facial nerve paralysis in children: is it as benign as supposed? Pediatr Neurol. 2013;49(3):178–181. doi: 10.1016/j.pediatrneurol.2013.03.013.
    1. Skogman BH, Glimaker K, Nordwall M, Vrethem M, Odkvist L, Forsberg P. Long-term clinical outcome after Lyme neuroborreliosis in childhood. Pediatrics. 2012;130(2):262–269. doi: 10.1542/peds.2011-3719.
    1. Peltomaa M, Saxen H, Seppala I, Viljanen M, Pyykko I. Paediatric facial paralysis caused by Lyme borreliosis: a prospective and retrospective analysis. Scand J Infect Dis. 1998;30(3):269–275. doi: 10.1080/00365549850160927.
    1. Lee M, Mackay M, Blackbourn L, Babl FE. Emotional impact of Bell's palsy in children. J Paediatr Child Health. 2014;50(3):245–246. doi: 10.1111/jpc.12541.
    1. Saadi R, Shokri T, Schaefer E, Hollenbeak C, Lighthall JG. Depression rates after facial paralysis. Ann Plast Surg. 2019;83(2):190–194. doi: 10.1097/SAP.0000000000001908.
    1. Roob G, Fazekas F, Hartung HP. Peripheral facial palsy: etiology, diagnosis and treatment. Eur Neurol. 1999;41(1):3–9. doi: 10.1159/000007990.
    1. Madhok VB, Gagyor I, Daly F, Somasundara D, Sullivan M, Gammie F, Sullivan F. Corticosteroids for Bell's palsy (idiopathic facial paralysis) Cochrane Database Syst Rev. 2016;7:Cd001942.
    1. Salinas RA, Alvarez G, Alvarez MI, Ferreira J. Corticosteroids for Bell's palsy (idiopathic facial paralysis). Cochrane Database Syst Rev. 2002, Issue 1. Art. No.:CD001942. 10.1002/14651858.CD001942
    1. Engstrom M, Berg T, Stjernquist-Desatnik A, Axelsson S, Pitkaranta A, Hultcrantz M, Kanerva M, Hanner P, Jonsson L. Prednisolone and valaciclovir in Bell's palsy: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2008;7(11):993–1000. doi: 10.1016/S1474-4422(08)70221-7.
    1. Sullivan FM, Swan IR, Donnan PT, Morrison JM, Smith BH, McKinstry B, Davenport RJ, Vale LD, Clarkson JE, Hammersley V, et al. Early treatment with prednisolone or acyclovir in Bell's palsy. N Engl J Med. 2007;357(16):1598–1607. doi: 10.1056/NEJMoa072006.
    1. Aljebab F, Choonara I, Conroy S. Systematic review of the toxicity of short-course oral corticosteroids in children. Arch Dis Child. 2016;101(4):365–370. doi: 10.1136/archdischild-2015-309522.
    1. Kasper WJ, Howe PM. Fatal varicella after a single course of corticosteroids. Pediatr Infect Dis J. 1990;9(10):729–732. doi: 10.1097/00006454-199010000-00009.
    1. Wu CT, Tsai SC, Lin JJ, Hsia SH. Disseminated varicella infection in a child receiving short-term steroids for asthma. Pediatr Dermatol. 2008;25(4):484–486. doi: 10.1111/j.1525-1470.2008.00720.x.
    1. Unuvar E, Oguz F, Sidal M, Kilic A. Corticosteroid treatment of childhood Bell's palsy. Pediatr Neurol. 1999;21(5):814–816. doi: 10.1016/S0887-8994(99)00099-5.
    1. Babl FE, Mackay MT, Borland ML, Herd DW, Kochar A, Hort J, Rao A, Cheek JA, Furyk J, Barrow L, et al. Bell's palsy in children (BellPIC): protocol for a multicentre, placebo-controlled randomized trial. BMC Pediatr. 2017;17(1):53. doi: 10.1186/s12887-016-0702-y.
    1. House JW, Brackmann DE. Facial nerve grading system. Otolaryngol Head Neck Surg. 1985;93(2):146–147. doi: 10.1177/019459988509300202.
    1. Mantsopoulos K, Psillas G, Psychogios G, Brase C, Iro H, Constantinidis J. Predicting the long-term outcome after idiopathic facial nerve paralysis. Otol Neurotol. 2011;32(5):848–851. doi: 10.1097/MAO.0b013e31821da2c6.
    1. Ross BG, Fradet G, Nedzelski JM. Development of a sensitive clinical facial grading system. Otolaryngol Head Neck Surg. 1996;114(3):380–386. doi: 10.1016/S0194-5998(96)70206-1.
    1. Kanerva M, Poussa T, Pitkaranta A. Sunnybrook and house-Brackmann facial grading systems: intrarater repeatability and interrater agreement. Otolaryngol Head Neck Surg. 2006;135(6):865–871. doi: 10.1016/j.otohns.2006.05.748.
    1. Neely JG, Cherian NG, Dickerson CB, Nedzelski JM. Sunnybrook facial grading system: reliability and criteria for grading. Laryngoscope. 2010;120(5):1038–1045.
    1. Marsk E, Bylund N, Jonsson L, Hammarstedt L, Engström M, Hadziosmanovic N, Berg T, Hultcrantz M. Prediction of nonrecovery in Bell's palsy using Sunnybrook grading. Laryngoscope. 2012;122(4):901–906. doi: 10.1002/lary.23210.
    1. Berg T, Jonsson L, Engstrom M. Agreement between the Sunnybrook, House-Brackmann, and Yanagihara facial nerve grading systems in Bell's palsy. Otol Neurotol. 2004;25(6):1020–1026. doi: 10.1097/00129492-200411000-00027.
    1. VanSwearingen JM, Brach JS. The facial disability index: reliability and validity of a disability assessment instrument for disorders of the facial neuromuscular system. Phys Ther. 1996;76(12):1288–1298. doi: 10.1093/ptj/76.12.1288.
    1. Mehta RP, WernickRobinson M, Hadlock TA. Validation of the Synkinesis assessment questionnaire. Laryngoscope. 2007;117(5):923–926. doi: 10.1097/MLG.0b013e3180412460.
    1. Kahn JB, Gliklich RE, Boyev KP, Stewart MG, Metson RB, McKenna MJ. Validation of a patient-graded instrument for facial nerve paralysis: the FaCE scale. Laryngoscope. 2001;111(3):387–398. doi: 10.1097/00005537-200103000-00005.
    1. Rebok G, Riley A, Forrest C, Starfield B, Green B, Robertson J, Tambor E. Elementary school-aged children's reports of their health: a cognitive interviewing study. Qual Life Res. 2001;10(1):59–70. doi: 10.1023/A:1016693417166.
    1. Lundgren-Laine H, Salantera S. Think-aloud technique and protocol analysis in clinical decision-making research. Qual Health Res. 2010;20(4):565–575. doi: 10.1177/1049732309354278.
    1. Skogman BH, Sjöwall J, Lindgren PE. The NeBoP score - a clinical prediction test for evaluation of children with Lyme Neuroborreliosis in Europe. BMC Pediatr. 2015;15:214. doi: 10.1186/s12887-015-0537-y.
    1. Zhang X, Lyu J, Tu J, Liu J, Lu X. Sample size calculations for comparing groups with binary outcomes. Shanghai Arch Psychiatry. 2017;29(5):316–324.
    1. Kimland E, Nydert P, Odlind V, Bottiger Y, Lindemalm S. Paediatric drug use with focus on off-label prescriptions at Swedish hospitals - a nationwide study. Acta Paediatr (Oslo, Norway : 1992) 2012;101(7):772–778. doi: 10.1111/j.1651-2227.2012.02656.x.
    1. Mc DTD, Joffe P, Taylor SE, Jones A, Cheek JA, Craig SS, Graudins A, Dhir R, Krieser D, Babl FE. Off-label and unlicenced medicine administration to paediatric emergency department patients. Emerg Med Australas. 2015;27(5):440–446. doi: 10.1111/1742-6723.12431.
    1. Sammons H. Ethical issues of clinical trials in children: a European perspective. Arch Dis Child. 2009;94(6):474–477. doi: 10.1136/adc.2008.149898.
    1. Choonara I. Unlicensed and off-label drug use in children: implications for safety. Expert Opin Drug Saf. 2004;3(2):81–83. doi: 10.1517/14740338.3.2.81.
    1. Regulation (EC) No 1901/2006 of the European Parliament and of the council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 (Text with EEA relevance) . Accessed 17 Mar 2021.
    1. Pediatric Research Equity Act of 2003. U.S. Statutes at Large 2003;117:1936-43.
    1. Jowett N, Gaudin RA, Banks CA, Hadlock TA. Steroid use in Lyme disease-associated facial palsy is associated with worse long-term outcomes. Laryngoscope. 2017;127(6):1451–1458. doi: 10.1002/lary.26273.
    1. Wormser GP, McKenna D, Scavarda C, Karmen C. Outcome of facial palsy from Lyme disease in prospectively followed patients who had received corticosteroids. Diagn Microbiol Infect Dis. 2018;91(4):336–338. doi: 10.1016/j.diagmicrobio.2018.03.016.
    1. Fattah AY, Gurusinghe AD, Gavilan J, Hadlock TA, Marcus JR, Marres H, Nduka CC, Slattery WH, Snyder-Warwick AK. Facial nerve grading instruments: systematic review of the literature and suggestion for uniformity. Plast Reconstr Surg. 2015;135(2):569–579. doi: 10.1097/PRS.0000000000000905.
    1. Bagger-Sjoback D, Remahl S, Ericsson M. Long-term outcome of facial palsy in neuroborreliosis. Otol Neurotol. 2005;26(4):790–795. doi: 10.1097/01.mao.0000178148.98762.00.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner